Prostate cancer is a hormone-dependent malignancy, whose onset and progression are
closely related to the activity of the androgen receptor (AR) signaling pathway. Due to this …

The success of inhibitor-based therapeutics is largely constrained by the acquisition of
therapeutic resistance, which is partially driven by the undruggable proteome. The …

Proteolysis targeting chimera (PROTAC) is an emerging protein degradation strategy, which
shows excellent advantages in targeting those so-called “undruggable” proteins. However …

Identifying host genes essential for Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) has the potential to reveal novel drug targets and further our understanding …

Hexokinase 2 (HK2) is the principal rate-limiting enzyme in the aerobic glycolysis pathway
and determines the quantity of glucose entering glycolysis. However, the current HK2 …

CBP/p300 proteins are key epigenetic regulators and promising targets for the treatment of
castration-resistant prostate cancer and other types of human cancers. Herein, we report the …

CBP/p300 are critical transcriptional coactivators of the androgen receptor (AR) and are
promising cancer therapeutic targets. Herein, we report the discovery of highly potent …

Over the last two decades, proteolysis targeting chimeras (PROTACs) have been
revolutionary in drug development rendering targeted protein degradation (TPD) as an …

Targeted protein degradation (TPD) technologies, particularly proteolysis-targeting chimeras
(PROTACs), have emerged as a significant advancement in drug discovery. However …

Targeted protein degradation (TPD) is emerging as a strategy to overcome the limitations of
traditional small-molecule inhibitors. Proteolysis targeting chimera (PROTAC) technology …